In 1979 over 50% of the Upjohn R&D budget was being spent on the prostaglandins. It was anticipated this class of molecules would have many applications and be highly profitable. Sadly this did not happen - the few prostaglandin products from this effort never even repaid the money spent on developing them. Below is an optimistic article from a 1979 American Pharmacy magazine.